Lucio Miele

Background

About Lucio Miele

Dr. Miele completed his medical training in Italy and his graduate training at the Max-Planck Institute for Molecular Genetics in Berlin. He then completed a fellowship in Human Genetics at the NIH (NICHD). There, he developed: 1) pharmacologically active peptides from human uteroglobin/CC10; 2) novel expression vectors to produce native, clinical-grade disulfide-bonded human proteins and 3) an early version of PCR-ELISA. In 1994, he moved to FDA/CBER as a senior investigator in the Division of Monoclonal Antibodies and member of the Division of Clinical Trials Design and Analysis. He was eventually promoted Acting Chief, Laboratory of Cell Biology. Dr. Miele authored the 1997 Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products. In 1994, he began working on mammalian Notch genes. In 1998, Dr. Miele moved to Loyola University's Cardinal Bernardin Cancer Center, where he discovered the anti-apoptotic activity of Notch1. He also created and oversaw a Molecular Pathology Core. In 2001, Dr. Miele moved to the University of Illinois at Chicago, as Program Director in the Cancer Center and Associate Professor of Biopharmaceutical Sciences. At UIC, Dr. Miele determined that Notch1 is necessary for Ras-induced transformation. In 2005, he returned to Loyola, as a Full Professor, Breast Cancer Program Director and eventually, Associate Cancer Center Director for Translational Sciences. In 2009, Dr. Miele was named Director of the UMMC Cancer Institute and Ergon Professor of Medicine. He held that post until his move to LSU Stanley S. Scott Cancer Center. Dr. Miele’s work is devoted to: 1) mechanism-based early clinical trials and mechanistic studies of cancer stem cell-regulatory genes such as Notch; 2) Correlation between GWAS data and transcriptome for cancer-associated genes. Dr. Miele has authored 270 publications in biomedical journals to date. He has served or serves as advisor to several pharmaceutical and biotechnology companies.